<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
	<channel>
	<link>http://salesandmarketingnetwork.com/hsmn_newsfeed_public.rss</link>
	<title>HSMN NewsFeed</title>
	<description><![CDATA[Healthcare Sales & Marketing Network NewsFeed]]></description>
	<lastBuildDate>Wed, 16 May 2012 22:33:20 CST</lastBuildDate>
	<language>en-us</language>
	<image>
	<title><![CDATA[The Healthcare Sales & Marketing Network]]></title>
	<width>150</width>
	<height>67</height>
	<link>http://salesandmarketingnetwork.com/news.php</link>
	<url>http://salesandmarketingnetwork.com/images/hsmn_logo_150.gif</url>
	</image>
	<item>
		 <title><![CDATA[Medtronic Receives Notification That U.S. Department of Justice and U.S. Attorney’s Office Have Closed Their Investigation of Activities Relating to INFUSE(R) Bone Graft]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035074</link>
			<pubDate>Wed, 16 May 2012 20:21:20 GMT</pubDate>
			<author><![CDATA[Medtronic]]></author>
		 <description><![CDATA[Closure Ends Federal Civil and Criminal Investigations of the Company

MINNEAPOLIS--(Healthcare Sales & Marketing Network)--Medtronic, Inc. (NYSE: MDT ) today announced it has been notified by the U.S. Department of Justice (DOJ) and the Office of the Un... <br/><font color="red">Devices, Orthopaedic, Neurosurgery</font><br/><font color="blue">Medtronic, INFUSE Bone Graft, Bone Graft</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Armando Anido Joins Respira Therapeutics, Inc. Board of Directors]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035073</link>
			<pubDate>Wed, 16 May 2012 20:13:04 GMT</pubDate>
			<author><![CDATA[Respira Therapeutics]]></author>
		 <description><![CDATA[AUSTIN, Texas, May 16, 2012  (HSMN NewsFeed)  -- Respira Therapeutics, Inc. (http://www.respiratherapeutics.com), developer of a breakthrough, excipient-free, high efficiency, dry powder inhaler (DPI) drug delivery technology for the treatment of respirato... <br/><font color="red">Devices, Drug Delivery, Personnel</font><br/><font color="blue">Respira Therapeutics, dry powder inhaler</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[STENTYS Self-Apposing(R) Stent shows very low mortality at one month in 1,000 high-risk heart attack patients]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035072</link>
			<pubDate>Wed, 16 May 2012 17:37:51 GMT</pubDate>
			<author><![CDATA[STENTYS]]></author>
		 <description><![CDATA[&quot;APPOSITION III&quot; study results reveal mortality at 1.2% compared to 3.5% in pooled analysis of conventional stents

PRINCETON, N.J. & PARIS--(Healthcare Sales & Marketing Network)--STENTYS S.A. (STNT.PA), a medical technology company commercial... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">STENTYS, Self-Apposing Stent, Acute Myocardial Infarction</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Mauna Kea Technologies Receives 510(k) Clearance for Portfolio of Smaller Diameter Cellvizio(R) Miniprobes]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035071</link>
			<pubDate>Wed, 16 May 2012 17:19:13 GMT</pubDate>
			<author><![CDATA[Mauna Kea Technologies]]></author>
		 <description><![CDATA[World's Smallest Microscope Gets Even Smaller 

PARIS--(Healthcare Sales & Marketing Network)- Mauna Kea Technologies (MKEA), leader in the endomicroscopy market and developer of Cellvizio&reg;, the world's smallest microscope, announced today that the U... <br/><font color="red">Devices, Gastroenterology, FDA</font><br/><font color="blue">Mauna Kea Technologies, Cellvizio, Confocal Laser Endomicroscopy</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035070</link>
			<pubDate>Wed, 16 May 2012 17:13:36 GMT</pubDate>
			<author><![CDATA[Epizyme]]></author>
		 <description><![CDATA[CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for patients with genetically-defined cancers, based on breakthroughs in the field of epigenetics, today a... <br/><font color="red">Biopharmaceuticals, Personalized Medicine, Personnel</font><br/><font color="blue">Epizyme, histone methyltransferase</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Roche and HYCOR Sign Global Distribution Agreement]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035069</link>
			<pubDate>Wed, 16 May 2012 17:10:43 GMT</pubDate>
			<author><![CDATA[HYCOR Biomedical]]></author>
		 <description><![CDATA[Agreement Expands HYCOR's KOVA Urinalysis Products into 130 Markets Worldwide

INDIANAPOLIS, May 16, 2012  (HSMN NewsFeed)  -- HYCOR Biomedical, Inc., a leading manufacturer of diagnostic products, and Roche today announced the signing of a global distri... <br/><font color="red">Diagnostics, Distribution</font><br/><font color="blue">HYCOR Biomedical, Roche Group, urinalysis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Mitralign Raises $35 Million Series D Financing]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035068</link>
			<pubDate>Wed, 16 May 2012 15:50:04 GMT</pubDate>
			<author><![CDATA[Mitralign]]></author>
		 <description><![CDATA[TEWKSBURY, Mass.--(Healthcare Sales & Marketing Network)--Mitralign, Inc., a cardiac device company leading the way in percutaneous mitral valve repair, today announced the closing of a $35 million Series D round of funding. The round was led by Forbion Ca... <br/><font color="red">Devices, Interventional Cardiology, Venture Capital</font><br/><font color="blue">Mitralign, annuloplasty, mitral valve, mitral regurgitation</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035067</link>
			<pubDate>Wed, 16 May 2012 13:38:02 GMT</pubDate>
			<author><![CDATA[Insmed]]></author>
		 <description><![CDATA[Company Also Announces Appointment of Randall Whitcomb, M.D. as Lead Independent Director

MONMOUTH JUNCTION, N.J., May 16, 2012  (HSMN NewsFeed)  -- Insmed Incorporated (INSM), a biopharmaceutical company, today announced the appointments of Donald J. H... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Insmed, inhaled antibiotic, antibiotic</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035066</link>
			<pubDate>Wed, 16 May 2012 13:33:54 GMT</pubDate>
			<author><![CDATA[NeuroSigma]]></author>
		 <description><![CDATA[Company sees potential for Thin-Film Nitinol in next-generation flow-diverting stents for treating intracranial aneurysms

LOS ANGELES, May 16, 2012  (HSMN NewsFeed)  -- NeuroSigma, Inc., a Los Angeles-based medical device company, today announced that i... <br/><font color="red">Devices, Interventional, Neurology, Acquisitions</font><br/><font color="blue">NeuroSigma, NSVascular, Nitinol, intracranial aneurysm</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Medtronic IN.PACT Drug-Eluting Balloon Studies Show Significant Benefit of Novel Medical Device in Treating Narrowed Arteries]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035065</link>
			<pubDate>Wed, 16 May 2012 13:29:11 GMT</pubDate>
			<author><![CDATA[Medtronic]]></author>
		 <description><![CDATA[Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Advantages Over Uncoated Angioplasty Balloons and Drug-Eluting Stents

PARIS--(Healthcare Sales & Marketing Network)-- Adding to the growing body of evidence on a novel interventional c... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Medtronic, PACIFIER, IN.PACT, drug eluting balloon, Paclitaxel</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[BIOTRONIK's Bioabsorbable Magnesium Scaffold Continues to Show Strong Results at 12 Months With Uncompromised Device Usability]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035064</link>
			<pubDate>Wed, 16 May 2012 13:24:14 GMT</pubDate>
			<author><![CDATA[BIOTRONIK]]></author>
		 <description><![CDATA[BUELACH, SWITZERLAND--(Healthcare Sales & Marketing Network)- Twelve-month results from the BIOSOLVE-I study with the DRug Eluting Absorbable Metal Scaffold (DREAMS) demonstrate safety and confirm vessel vasomotion. The results from the BIOSOLVE-I study we... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">BIOTRONIK, Drug Eluting Absorbable Metal Scaffold, BIOSOLVE-I</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Elixir Medical Announces Excellent Results from DESolve I First-In-Man Study for the Fully Bioresorbable Drug Eluting Coronary Scaffold System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035063</link>
			<pubDate>Wed, 16 May 2012 13:18:49 GMT</pubDate>
			<author><![CDATA[Elixir Medical]]></author>
		 <description><![CDATA[Unparalleled Data Shows Exceptionally Low Late-Lumen Loss, 0% Binary Restenosis and Low Neo-Intimal Volume Obstruction for Ground-Breaking Technology at EuroPCR 2012 Scientific Conference

SUNNYVALE, Calif. & PARIS--(Healthcare Sales & Marketing Network)... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Elixir Medical, DESolve , Bioresorbable Coronary Scaffold</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sorin Group Receives Regulatory Approval to Market Memo 3D(TM) Annuloplasty Ring in Japan]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035062</link>
			<pubDate>Wed, 16 May 2012 13:13:17 GMT</pubDate>
			<author><![CDATA[Sorin Group]]></author>
		 <description><![CDATA[TOKYO--(Healthcare Sales & Marketing Network)--Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announces that it received authorization from the Japanese Pharmaceuticals and Me... <br/><font color="red">Devices, Cardiology, Regulatory</font><br/><font color="blue">Sorin Group, MEMO 3D, Annuloplasty Ring</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035061</link>
			<pubDate>Wed, 16 May 2012 13:06:52 GMT</pubDate>
			<author><![CDATA[St. Jude Medical]]></author>
		 <description><![CDATA[Use of EnligHTN technology resulted in a 28 point reduction of systolic blood pressure on average after 1 month

Trial showed double the reduction in blood pressure of competitive technology in the same timeframe

ST. PAUL, Minn. & PARIS--(Healthcare S... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">St. Jude Medical, EnligHTN, renal denervation, hypertension</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Piramal Healthcare Limited to Acquire Decision Resources Group]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035060</link>
			<pubDate>Wed, 16 May 2012 13:01:41 GMT</pubDate>
			<author><![CDATA[Piramal Healthcare]]></author>
		 <description><![CDATA[Decision Resources Group (DRG) acquisition at approximately Rs. 3,400 Cr

DRG a fast growing healthcare information business - CAGR 20% from 2006 to 2011

DRG's client base includes 48 out of top 50 global pharma companies

MUMBAI, India and BURLINGT... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">Piramal Healthcare, Decision Resources Group</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035059</link>
			<pubDate>Wed, 16 May 2012 12:54:37 GMT</pubDate>
			<author><![CDATA[Genentech]]></author>
		 <description><![CDATA[First Pivotal Phase III Data on Genentech’s Antibody-Drug Conjugate Trastuzumab Emtansine (T-DM1) in Advanced HER2-Positive Metastatic Breast Cancer

Phase III Data on Avastin in Advanced Colorectal and Ovarian Cancers

SOUTH SAN FRANCISCO, Calif.--(He... <br/><font color="red">Biopharmaceuticals, Oncology</font><br/><font color="blue">Genentech, Roche Group, trastuzumab emtansine, HER2, breast cancer, Avastin</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[CryoLife to Acquire Hemosphere]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035058</link>
			<pubDate>Tue, 15 May 2012 21:50:43 GMT</pubDate>
			<author><![CDATA[CryoLife]]></author>
		 <description><![CDATA[HeRO&reg; Graft is Standard of Care to Establish Permanent Access for Catheter Dependent Hemodialysis Patients

Leverages CryoLife's Cardiovascular Sales Force to Accelerate HeRO Graft Growth in $250+ Million Worldwide Market Opportunity

Conference Ca... <br/><font color="red">Devices, Mergers & Acquisitions</font><br/><font color="blue">CryoLife, Hemosphere, HeRO Graft, ESRD</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY(TM) Stent Versus PROMUS Element(TM) Platinum Chromium Stent]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035057</link>
			<pubDate>Tue, 15 May 2012 17:36:01 GMT</pubDate>
			<author><![CDATA[Boston Scientific]]></author>
		 <description><![CDATA[Follow-up Data from EVOLVE Trial Presented at EuroPCR; Trial is Evaluating Next-Generation Everolimus-Eluting Platinum Chromium Coronary Stent with Ultra-Thin Bioabsorbable Abluminal Polymer

NATICK, Mass., May 15, 2012  (HSMN NewsFeed)  -- Boston Scient... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Boston Scientific, Everolimus, drug eluting stent, Coronary Stent</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Boston Scientific Announces Positive Data From Lotus(TM) Transcatheter Aortic Valve Trial]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035056</link>
			<pubDate>Tue, 15 May 2012 17:13:23 GMT</pubDate>
			<author><![CDATA[Boston Scientific]]></author>
		 <description><![CDATA[Results of REPRISE I Study Suggest Device Minimizes Aortic Regurgitation

NATICK, Mass., May 15, 2012  (HSMN NewsFeed)  -- Boston Scientific Corporation (BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Boston Scientific, Transcatheter Aortic Valve, heart valve, valve replacement</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Elixir Medical Announces Continued Excellent One Year Safety and Efficacy Data from the EXCELLA BD Randomized Clinical Trial for DESyne BD(TM) Novolimus Eluting Coronary Stent with Biodegradable Polymer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035055</link>
			<pubDate>Tue, 15 May 2012 17:08:33 GMT</pubDate>
			<author><![CDATA[Elixir Medical]]></author>
		 <description><![CDATA[SUNNYVALE, Calif.--(Healthcare Sales & Marketing Network)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced one-year randomized clinical trial results today demonstra... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Elixir Medical, DESyne BD, Novolimus, drug eluting stent</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[AXIOS(TM) Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035054</link>
			<pubDate>Tue, 15 May 2012 17:05:43 GMT</pubDate>
			<author><![CDATA[Xlumena]]></author>
		 <description><![CDATA[Peer-Reviewed Paper Validates Promise of New Transenteric Therapy

MOUNTAIN VIEW, Calif., May 15, 2012  (HSMN NewsFeed)  -- Xlumena, Inc. announces the publication of a scientific paper describing the first human study of the AXIOS™ Stent and Delivery Sy... <br/><font color="red">Devices, Gastroenterology</font><br/><font color="blue">Xlumena, AXIOS Stent, pancreatic pseudocyst, cholecystitis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Promedior Appoints Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035053</link>
			<pubDate>Tue, 15 May 2012 16:56:45 GMT</pubDate>
			<author><![CDATA[Promedior]]></author>
		 <description><![CDATA[Company to Accelerate Product Development Focus in Fibrotic Diseases

Company to Relocate Headquarters to Boston Area 

MALVERN, Penn.--(Healthcare Sales & Marketing Network)--Promedior, Inc., a clinical stage biotechnology company developing novel bio... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Promedior, pulmonary fibrosis, myelofibrosis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Alliqua Announces Changes to Its Board of Directors]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035052</link>
			<pubDate>Tue, 15 May 2012 16:53:05 GMT</pubDate>
			<author><![CDATA[Alliqua]]></author>
		 <description><![CDATA[NEW YORK, May 15, 2012 --(HSMN NewsFeed) -- Alliqua, Inc. (OTCBB:ALQA.OB ) (&quot;Alliqua&quot; or the &quot;Company&quot;) announced the appointment of Kenneth Londoner to its Board of Directors and Michael Goldberg, M.D. to its recently formed Scientific... <br/><font color="red">Devices, Drug Delivery, Personnel</font><br/><font color="blue">Alliqua, transdermal, hydrogel</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[AxioMed Spine Corporation Receives CE Mark for Freedom(R) Cervical Disc]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035051</link>
			<pubDate>Tue, 15 May 2012 16:50:15 GMT</pubDate>
			<author><![CDATA[AxioMed Spine]]></author>
		 <description><![CDATA[GARFIELD HEIGHTS, Ohio--(Healthcare Sales & Marketing Network)--AxioMed&reg; Spine Corporation (www.axiomed.com) announces the receipt of CE Mark approval for its Freedom&reg; Cervical Disc, an elastomeric total spinal disc replacement device. The CE Mark ... <br/><font color="red">Devices, Orthopaedic, Neurosurgery, Regulatory</font><br/><font color="blue">AxioMed Spine, Freedom Cervical Disc, artificial disc</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[BSD Medical Completes Implementation of New MicroThermX(R) Direct Sales Program in Major U.S. Metropolitan Areas]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035050</link>
			<pubDate>Tue, 15 May 2012 16:35:19 GMT</pubDate>
			<author><![CDATA[BSD Medical]]></author>
		 <description><![CDATA[SALT LAKE CITY--(Healthcare Sales & Marketing Network)--BSD Medical Corporation (NASDAQ:BSDM ) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced that the Company has completed ... <br/><font color="red">Devices, Oncology, Surgery, Distribution</font><br/><font color="blue">BSD Medical, MicroThermX, Microwave Ablation</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Covalon Announces Major Milestone: Achieves FDA Approval for IV Clear(TM) - a Breakthrough Antimicrobial Silicone Adhesive Film Dressing for Securing Vascular Access Medical Devices]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035049</link>
			<pubDate>Tue, 15 May 2012 16:29:08 GMT</pubDate>
			<author><![CDATA[Covalon Technologies]]></author>
		 <description><![CDATA[MISSISSAUGA, ON, May 15, 2012  (HSMN NewsFeed)  - Covalon Technologies Ltd. (the &quot;Company&quot; or &quot;Covalon&quot;) (COV.V), an advanced medical technologies company, today announced United States Food and Drug Administration (&quot;FDA&quot;) app... <br/><font color="red">Devices, FDA</font><br/><font color="blue">Covalon Technologies, IV Clear</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Abbott's XIENCE PRIME(TM) and XIENCE V(R) Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035048</link>
			<pubDate>Tue, 15 May 2012 13:54:39 GMT</pubDate>
			<author><![CDATA[Abbott]]></author>
		 <description><![CDATA[Three-Month Dual Anti-Platelet Therapy (DAPT) is Shortest Duration For Any Major Drug Eluting Stent in Europe

New Indication Supported by Data From More Than 10,000 Patients

PARIS, May 15, 2012  (HSMN NewsFeed)  -- Abbott (ABT) today announced that t... <br/><font color="red">Devices, Interventional Cardiology, Regulatory</font><br/><font color="blue">Abbott, XIENCE PRIME, XIENCE V , Everolimus, dual anti-platelet therapy</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Jim Cunniff Named Senior Vice President, Leading Commercial Activities in the Americas for KCI]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035047</link>
			<pubDate>Tue, 15 May 2012 13:49:21 GMT</pubDate>
			<author><![CDATA[Kinetic Concepts]]></author>
		 <description><![CDATA[SAN ANTONIO--(Healthcare Sales & Marketing Network)--Kinetic Concepts, Inc. announced today that James (Jim) Cunniff has been named Senior Vice President of the Americas.

As Senior Vice President, Cunniff will be responsible for commercial activities in... <br/><font color="red">Devices, Wound Care, Personnel</font><br/><font color="blue">Kinetic Concepts, V.A.C. Therapy, negative pressure wound therapy</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Todd Campbell Appointed Vice President of Operations of ValveXchange, Inc.]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035046</link>
			<pubDate>Tue, 15 May 2012 13:46:55 GMT</pubDate>
			<author><![CDATA[ValveXchange]]></author>
		 <description><![CDATA[DENVER--(Healthcare Sales & Marketing Network)--ValveXchange is pleased to announce the appointment of Mr. Todd D. Campbell as Vice President of Operations.

Mr. Campbell has been Sr. Executive Director of Product Development at ValveXchange since 2011, ... <br/><font color="red">Devices, Cardiology, Personnel</font><br/><font color="blue">ValveXchange, heart valve, valve replacement</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sonitus Medical Closes $25 Million Series D Round Of Venture Capital Financing]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035045</link>
			<pubDate>Tue, 15 May 2012 13:42:29 GMT</pubDate>
			<author><![CDATA[Sonitus Medical]]></author>
		 <description><![CDATA[New Investor Abingworth Leads Round; Takes Board Seat.

SAN MATEO, Calif., May 15, 2012  (HSMN NewsFeed)  -- Sonitus Medical, Inc., a medical device company that manufactures the world's first non-surgical and removable hearing device to transmit sound v... <br/><font color="red">Devices, Venture Capital</font><br/><font color="blue">Sonitus Medical, SoundBite</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cappella Medical to Share Long Term Clinical Benefits of its Sideguard(R) Technology at EuroPCR 2012]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035044</link>
			<pubDate>Tue, 15 May 2012 13:31:38 GMT</pubDate>
			<author><![CDATA[Cappella Medical Devices]]></author>
		 <description><![CDATA[PARIS--(Healthcare Sales & Marketing Network)--Cappella Medical Devices Ltd (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, is pleased to announce new long term follow up clinical data fo... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Cappella Medical Devices, Sideguard, coronary sidebranch, bifurcation</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035043</link>
			<pubDate>Tue, 15 May 2012 13:24:06 GMT</pubDate>
			<author><![CDATA[Svelte Medical Systems]]></author>
		 <description><![CDATA[NEW PROVIDENCE, N.J.--(Healthcare Sales & Marketing Network)--Svelte&reg; Medical Systems today announced completion of enrollment in the DIRECT (Direct Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study conducted at four in... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Svelte Medical Systems, Rapamycin, sirolimus, drug eluting stent, Svelte system</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Toshiba Installs First Aquilion PRIME CT in U.S.]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035042</link>
			<pubDate>Tue, 15 May 2012 13:19:43 GMT</pubDate>
			<author><![CDATA[Toshiba America Medical Systems]]></author>
		 <description><![CDATA[SDMI Uses Advanced CT System to Conduct Lower Dose, Faster Exams for Improved Throughput and Patient Care

TUSTIN, Calif.--(Healthcare Sales & Marketing Network)--To reduce radiation dose while maintaining high image quality, Steinberg Diagnostic Medical... <br/><font color="red">Devices, Radiology</font><br/><font color="blue">Toshiba America Medical Systems, Aquilion PRIME, CT, imaging</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Arterial Remodeling Technologies (“ART”) receives regulatory approval to begin First-In-Man “ARTDIVA” clinical trial with its next-generation bioresorbable stent]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035041</link>
			<pubDate>Tue, 15 May 2012 13:15:45 GMT</pubDate>
			<author><![CDATA[Arterial Remodeling Technologies]]></author>
		 <description><![CDATA[Principal investigator is Jean Fajadet, M.D.

“Our analysis of ART’s in vivo data confirms that stent dismantling is occurring at around three months, and the overall safety data look encouraging thus far.” - Renu Virmani, MD, Medical Director/President,... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Arterial Remodeling Technologies , bioresorbable stent, arterial remodeling</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[New Executive Vice President Commercial Appointed]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035040</link>
			<pubDate>Tue, 15 May 2012 13:09:01 GMT</pubDate>
			<author><![CDATA[Medivir]]></author>
		 <description><![CDATA[STOCKHOLM, May 15, 2012  (HSMN NewsFeed)  --Medivir AB (MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, announced today that it has appointed Henric Juserius to be the new head of the company's commercial activities... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Medivir, Xerese, Xerclear</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[St. Jude Medical Announces European Approval and Launch of the EnligHTN Renal Denervation System for Treatment of Hypertension]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035039</link>
			<pubDate>Tue, 15 May 2012 13:04:19 GMT</pubDate>
			<author><![CDATA[St. Jude Medical]]></author>
		 <description><![CDATA[Decades of experience in ablation technologies used to develop the industry’s first multi-electrode technology for renal denervation

ST. PAUL, Minn. & PARIS--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (NYSE:STJ ), a global medical de... <br/><font color="red">Devices, Interventional Cardiology, Regulatory</font><br/><font color="blue">St. Jude Medical, EnligHTN , renal denervation, hypertension</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Spinal Kinetics Wins Another Round in Synthes' Patent Litigation]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035038</link>
			<pubDate>Tue, 15 May 2012 12:59:10 GMT</pubDate>
			<author><![CDATA[Spinal Kinetics]]></author>
		 <description><![CDATA[Synthes German Patent Action Is Dismissed

SUNNYVALE, CA--(Healthcare Sales & Marketing Network)- Spinal Kinetics, Inc., the designer and manufacturer of the innovative M6&reg; Artificial Disc, today announced that the German District Court in Mannheim h... <br/><font color="red">Devices, Neurosurgery, Orthopaedic, Litigation</font><br/><font color="blue">Spinal Kinetics, Synthes, M6, Artificial Disc, degenerative disc disease</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[STENTYS Expands Its Product Offerings for Treating Heart Attacks]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035037</link>
			<pubDate>Mon, 14 May 2012 15:46:46 GMT</pubDate>
			<author><![CDATA[STENTYS]]></author>
		 <description><![CDATA[PRINCETON, N.J. & PARIS--(Healthcare Sales & Marketing Network)--STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing&reg; Stent to treat Acute Myocardial Infarction (AMI), announced today that it is... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">STENTYS, Self-Apposing Stent, Acute Myocardial Infarction</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Boston Scientific Announces CE Mark and European Launch of Innova(TM) Self-expanding Bare-metal Stent System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035036</link>
			<pubDate>Mon, 14 May 2012 15:42:30 GMT</pubDate>
			<author><![CDATA[Boston Scientific]]></author>
		 <description><![CDATA[Innovative Stent Designed to Treat Peripheral Vascular Lesions for Stenoses in Arteries above the Knee

NATICK, Mass., May 14, 2012   (HSMN NewsFeed)  -- Boston Scientific Corporation (BSX) announces CE Mark and European market launch of the Innova™ Self... <br/><font color="red">Devices, Interventional, Regulatory</font><br/><font color="blue">Boston Scientific, Self-Expanding Stent, Bare-Metal Stent</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Bioness Announces FDA Clearance of Smaller Leg Cuff for Use with Its L300 Foot Drop System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035035</link>
			<pubDate>Mon, 14 May 2012 15:40:03 GMT</pubDate>
			<author><![CDATA[Bioness]]></author>
		 <description><![CDATA[Technology to Improve Walking in Individuals with Central Nervous System Disorders Now Available to Patients with Smaller Calf Sizes

VALENCIA, Calif.--(Healthcare Sales & Marketing Network)--Bioness Inc. today announced it has received 510(k) clearance ... <br/><font color="red">Devices, Neurology, FDA</font><br/><font color="blue">Bioness, L300, Foot Drop, neuromodulation</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035034</link>
			<pubDate>Mon, 14 May 2012 15:36:24 GMT</pubDate>
			<author><![CDATA[Boston Scientific]]></author>
		 <description><![CDATA[Collaboration expected to improve access to imaging data used to treat patients

NATICK and ANDOVER, Mass., May 14, 2012  (HSMN NewsFeed)  -- Boston Scientific Corporation (BSX) and Royal Philips Electronics (NYSE: PHG, AEX: PHI) announced a collaboratio... <br/><font color="red">Devices, Interventional Cardiology, Radiology</font><br/><font color="blue">Boston Scientific, Royal Philips Electronics, imaging</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035033</link>
			<pubDate>Mon, 14 May 2012 15:31:40 GMT</pubDate>
			<author><![CDATA[Ohr Pharmaceutical]]></author>
		 <description><![CDATA[Expects to Commence Phase II Clinical Trial in Third Quarter 2012 

NEW YORK, NY--(Healthcare Sales & Marketing Network)- Ohr Pharmaceutical Inc. (OTC.BB: OHRP) announced today that its Squalamine Eye Drops, a potent inhibitor of multiple growth factors ... <br/><font color="red">Biopharmaceuticals, Ophthalmology, FDA</font><br/><font color="blue">Ohr Pharmaceutical, Squalamine, Wet-AMD, macular degeneration</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega(R) Intra-Aortic Balloon Catheter Sizes]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035032</link>
			<pubDate>Mon, 14 May 2012 15:25:59 GMT</pubDate>
			<author><![CDATA[MAQUET Cardiovascular]]></author>
		 <description><![CDATA[Introducing the Complete Mega Iab Family: Higher Efficacy for Any-Sized Patient

MAHWAH, N.J., May 14, 2012  (HSMN NewsFeed)  -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) cle... <br/><font color="red">Devices, Cardiology, FDA</font><br/><font color="blue">MAQUET Cardiovascular, intra-aortic balloon, STATLOCK</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[St. Jude Medical Continues Strong Show of PCI Optimization Technologies at EuroPCR]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035031</link>
			<pubDate>Mon, 14 May 2012 15:22:12 GMT</pubDate>
			<author><![CDATA[St. Jude Medical]]></author>
		 <description><![CDATA[New technology, symposia and a FAME II data presentation keep St. Jude Medical at the forefront of PCI Optimization

ST. PAUL, Minn. & PARIS--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (NYSE:STJ ), a global medical device company, tod... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">St. Jude Medical, PressureWire, Fractional Flow Reserve</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical and Regulatory Affairs]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035030</link>
			<pubDate>Mon, 14 May 2012 15:18:43 GMT</pubDate>
			<author><![CDATA[Synthetic Biologics]]></author>
		 <description><![CDATA[Former Chief Medical Officer of Clinical Data, Inc. Brings Extensive Clinical Development and Regulatory Experience to Company

ANN ARBOR, Mich., May 14, 2012  (HSMN NewsFeed)  -- Synthetic Biologics, Inc. (SYN), a developer of synthetic DNA-based therap... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Synthetic Biologics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[ReCor Medical Completes REDUCE Pilot Clinical Study of Its PARADISE(TM) Ultrasound Transcatheter Renal Denervation System for Treating Resistant Hypertension]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035029</link>
			<pubDate>Mon, 14 May 2012 15:16:16 GMT</pubDate>
			<author><![CDATA[ReCor Medical]]></author>
		 <description><![CDATA[Data to be presented at this week’s EuroPCR 2012 congress, Paris

MENLO PARK, Calif.--(Healthcare Sales & Marketing Network)--ReCor Medical, an emerging medical device company, announced today that it has completed enrollment in the REDUCE 15-patient pil... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">ReCor Medical, renal denervation, hypertension</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Piramal Healthcare Presents Positive Results of Pivotal Phase III Clinical Trial for BST-CarGel(R) at the World Congress of the International Cartilage Repair Society (ICRS)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035028</link>
			<pubDate>Mon, 14 May 2012 12:49:29 GMT</pubDate>
			<author><![CDATA[Piramal Healthcare]]></author>
		 <description><![CDATA[BST-CarGel&reg; treatment results in more repair cartilage of higher quality than microfracture, the current orthopaedic standard of care, with a similar safety profile

The BST-CarGel&reg; trial met both co-primary endpoints by achieving statistical sig... <br/><font color="red">Devices, Orthopaedic</font><br/><font color="blue">Piramal Healthcare, BST-CarGel, regenerated cartilage</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Study of First-in-Class WATCHMAN(R) Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035027</link>
			<pubDate>Fri, 11 May 2012 17:59:48 GMT</pubDate>
			<author><![CDATA[Boston Scientific]]></author>
		 <description><![CDATA[Results Presented at Heart Rhythm Society from ASA Plavix Study Evaluating Boston Scientific Left Atrial Appendage Closure Device

NATICK and BOSTON, Mass., May 11, 2012  (HSMN NewsFeed)  -- Boston Scientific Corporation (BSX) announces results from the ... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Boston Scientific, WATCHMAN, Left Atrial Appendage, Atrial Fibrillation</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[New Data from Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035026</link>
			<pubDate>Fri, 11 May 2012 17:53:39 GMT</pubDate>
			<author><![CDATA[Medtronic]]></author>
		 <description><![CDATA[Study Reinforces Clinical and Economic Validity of Expanded Indication for Medtronic CRT-D Devices

MINNEAPOLIS & BOSTON--(Healthcare Sales & Marketing Network)--Medtronic, Inc. (NYSE: MDT ) today announced findings from an economic analysis of the landm... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">Medtronic, cardiac resynchronization therapy, ICD, heart failure</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[BIOTRONIK Adds New Reocor External Pacemaker to Its External Product Portfolio]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035025</link>
			<pubDate>Fri, 11 May 2012 17:50:40 GMT</pubDate>
			<author><![CDATA[BIOTRONIK]]></author>
		 <description><![CDATA[Reocor combines intuitive, high quality design with unprecedented longevity

LAKE OSWEGO, Ore.--(Healthcare Sales & Marketing Network)--BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two ... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">BIOTRONIK, Reocor, pacemaker</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Lannett Company Adds Paul Taveira to Board of Directors]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035024</link>
			<pubDate>Fri, 11 May 2012 15:49:13 GMT</pubDate>
			<author><![CDATA[Lannett Company]]></author>
		 <description><![CDATA[PHILADELPHIA--(Healthcare Sales & Marketing Network)--Lannett Company, Inc. (NYSE Amex: LCI), a manufacturer of generic pharmaceuticals, today announced the appointment of Paul Taveira to its board of directors, expanding the company’s board to eight membe... <br/><font color="red">Biopharmaceuticals, Generics, Personnel</font><br/><font color="blue">Lannett Company</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[CellTherapeutics’ Pixuvri(R) Approved in EU as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035023</link>
			<pubDate>Fri, 11 May 2012 15:47:41 GMT</pubDate>
			<author><![CDATA[CellTherapeutics]]></author>
		 <description><![CDATA[SEATTLE & MILAN--(Healthcare Sales & Marketing Network)--CellTherapeutics today announced that it has received conditional marketing authorization from the European Commission for Pixuvri&reg; (pixantrone) as monotherapy for the treatment of adult patients... <br/><font color="red">Biopharmaceuticals, Oncology, Regulatory</font><br/><font color="blue">CellTherapeutics, Pixuvri, pixantrone, non-Hodgkin B-cell lymphoma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[InVivo Therapeutics Adds Senior Leadership in Manufacturing and Cell Research]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035022</link>
			<pubDate>Fri, 11 May 2012 15:45:10 GMT</pubDate>
			<author><![CDATA[InVivo Therapeutics]]></author>
		 <description><![CDATA[Jack Harvey and Celina Chang Join InVivo from Pervasis Therapeutics

CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), announced today the appointment of Jack Harvey as Senior Director of Manufac... <br/><font color="red">Biopharmaceuticals, Neurology, Personnel</font><br/><font color="blue">InVivo Therapeutics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[AmerisourceBergen Names Tim G. Guttman Senior Vice President and Chief Financial Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035021</link>
			<pubDate>Fri, 11 May 2012 15:41:27 GMT</pubDate>
			<author><![CDATA[AmerisourceBergen]]></author>
		 <description><![CDATA[VALLEY FORGE, Pa.--(Healthcare Sales & Marketing Network)--AmerisourceBergen Corporation (NYSE: ABC ) today announced that Tim G. Guttman, 53, has been named Senior Vice President and Chief Financial Officer, effective immediately. Guttman will report to S... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">AmerisourceBergen</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[RyMed Technologies Wins Patent Infringement Case]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035020</link>
			<pubDate>Fri, 11 May 2012 15:39:41 GMT</pubDate>
			<author><![CDATA[RyMed Technologies]]></author>
		 <description><![CDATA[Federal Jury Rules Unanimously for RyMed, against ICU Medical

FRANKLIN, Tenn.--(Healthcare Sales & Marketing Network)--A federal jury has found in favor of RyMed Technologies and against ICU Medical (Nasdaq: ICUI) in a closely-watched patent infringemen... <br/><font color="red">Devices, Litigation</font><br/><font color="blue">RyMed Technologies, ICU Medical</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion(TM) for the Treatment of Chronic Pain of Osteoarthritis of the Knee and Schedules May 16th Webcast to Update Shareholders]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035019</link>
			<pubDate>Fri, 11 May 2012 15:36:48 GMT</pubDate>
			<author><![CDATA[Ampio Pharmaceuticals]]></author>
		 <description><![CDATA[GREENWOOD VILLAGE, Colo., May 11, 2012  (HSMN NewsFeed)  -- Ampio Pharmaceuticals, Inc. (AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™) announced completion of a pre-IND meeting with th... <br/><font color="red">Biopharmaceuticals, FDA</font><br/><font color="blue">Ampio Pharmaceuticals, Ampion, osteoarthritis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035018</link>
			<pubDate>Fri, 11 May 2012 15:33:11 GMT</pubDate>
			<author><![CDATA[Takeda Pharmaceutical]]></author>
		 <description><![CDATA[Patients in the trial had failed at least one conventional therapy

OSAKA, Japan--(Healthcare Sales & Marketing Network)--Takeda Pharmaceutical Company Limited (TSE:4502) today announced top-line results from the international, randomized, placebo-contro... <br/><font color="red">Biopharmaceuticals, Gastroenterology</font><br/><font color="blue">Takeda Pharmaceutical, Vedolizumab, Crohn's disease</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cardionovum(R) Will Launch Two Drug-Eluting Balloon (DEB) Dilatation Catheter Product Families at EuroPCR 2012]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035017</link>
			<pubDate>Thu, 10 May 2012 19:00:46 GMT</pubDate>
			<author><![CDATA[Cardionovum]]></author>
		 <description><![CDATA[“We have opened a whole new dimension for the clinically advanced treatment of coronary and endovascular artery disease.”

- Dr. Michael Orlowski, CEO

Booth F23, Palais des Congr&egrave;s, Paris 

BONN, Germany--(Healthcare Sales & Marketing Network... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Cardionovum, drug-eluting balloon, paclitaxel</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[FDA Approves BIOTRONIK Next Generation ICDs and CRT-Ds]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035016</link>
			<pubDate>Thu, 10 May 2012 18:58:03 GMT</pubDate>
			<author><![CDATA[BIOTRONIK]]></author>
		 <description><![CDATA[Lumax 740 series offers meaningful innovations to address patients’ needs as their cardiac condition changes

LAKE OSWEGO, Ore.--(Healthcare Sales & Marketing Network)--BIOTRONIK, a leading manufacturer of innovative medical technology, has received FDA ... <br/><font color="red">Devices, Cardiology, FDA</font><br/><font color="blue">BIOTRONIK, implantable cardioverter defibrillator</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Loma Vista Medical receives CE mark for its TRUE Dilatation(TM) Balloon Valvuloplasty Catheter]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035015</link>
			<pubDate>Thu, 10 May 2012 18:55:44 GMT</pubDate>
			<author><![CDATA[Loma Vista Medical]]></author>
		 <description><![CDATA[World’s first ultra-precise balloon specifically designed to prevent balloon ruptures in BAV and TAVI procedures will be launched at EuroPCR congress for cardiologists and surgeons in Paris next week.

“It is clearly established that heart valve companie... <br/><font color="red">Devices, Interventional Cardiology, Regulatory</font><br/><font color="blue">Loma Vista Medical, TRUE Dilatation, Balloon Valvuloplasty Catheter</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Interrad Medical Announces FDA Clearance for Additional Sizes of the SecurAcath Device]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035014</link>
			<pubDate>Thu, 10 May 2012 18:50:40 GMT</pubDate>
			<author><![CDATA[Interrad Medical]]></author>
		 <description><![CDATA[MINNEAPOLIS--(Healthcare Sales & Marketing Network)--Interrad Medical, Inc. a privately held medical device company, announced today that it has received FDA clearance for four new sizes of the SecurAcath subcutaneous catheter securement device. In respons... <br/><font color="red">Devices, FDA</font><br/><font color="blue">Interrad Medical, SecurAcath</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows Similar Safety Profile When Compared to Budesonide Monotherapy in African-American Patients with Asthma]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035013</link>
			<pubDate>Thu, 10 May 2012 18:48:09 GMT</pubDate>
			<author><![CDATA[AstraZeneca]]></author>
		 <description><![CDATA[52-week Safety Data Published in The Journal of Allergy and Clinical Immunology

WILMINGTON, Del.--(Healthcare Sales & Marketing Network)--AstraZeneca (NYSE:AZN ) today announced the publication of data demonstrating that SYMBICORT Inhalation Aerosol 320... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">AstraZeneca, SYMBICORT, budesonide, formoterol, asthma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sorin Group Announces FDA Approval and Commercial Launch of Complete Portfolio of Implantable Heart Device Leads]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035012</link>
			<pubDate>Thu, 10 May 2012 18:43:30 GMT</pubDate>
			<author><![CDATA[Sorin Group]]></author>
		 <description><![CDATA[New pacing, defibrillation and left ventricular leads, combined with Sorin Group’s innovative implantable devices enable effective management of arrhythmias and heart failure

BOSTON--(Healthcare Sales & Marketing Network)--Sorin Group, (Reuters Code: SO... <br/><font color="red">Devices, Cardiology, FDA</font><br/><font color="blue">Sorin Group, pacing leads, defibrillation leads, left ventricular leads</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Internal Fixation Systems Enters Into a Distribution Agreement With Intelligent Orthopaedics]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035011</link>
			<pubDate>Thu, 10 May 2012 13:09:19 GMT</pubDate>
			<author><![CDATA[Internal Fixation Systems]]></author>
		 <description><![CDATA[MIAMI, May 10, 2012 --(HSMN NewsFeed) -- Internal Fixation Systems (OTCQB:IFIX.OB ) announced today that it has entered into a distribution agreement with Intelligent Orthopaedics Ltd. (IO) to market its Staffordshire Orthopaedic Reduction Machine (STORM) ... <br/><font color="red">Devices, Orthopaedic, Distribution</font><br/><font color="blue">Internal Fixation Systems, Intelligent Orthopaedics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Boston Scientific Announces Schedule For EuroPCR 2012]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035010</link>
			<pubDate>Thu, 10 May 2012 13:05:27 GMT</pubDate>
			<author><![CDATA[Boston Scientific]]></author>
		 <description><![CDATA[Clinical Presentations to Include 12-month Outcomes Data from EVOLVE Trial and Results of the REPRISE I Trial

NATICK, Mass., May 10, 2012  (HSMN NewsFeed)  -- Boston Scientific Corporation (BSX) announces its schedule of major events and sponsored clini... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Boston Scientific, drug eluting stent, aortic valve, left atrial appendage</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Incline Therapeutics Announces Appointment of John Tucker as Chief Commercial Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035009</link>
			<pubDate>Thu, 10 May 2012 13:00:56 GMT</pubDate>
			<author><![CDATA[Incline Therapeutics]]></author>
		 <description><![CDATA[REDWOOD CITY, Calif., May 10, 2012  (HSMN NewsFeed)  -- Incline Therapeutics, Inc., a hospital-focused specialty pharmaceutical company, announced today the appointment of John Tucker as Senior Vice President and Chief Commercial Officer.  Mr. Tucker has 2... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Incline Therapeutics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Tris Pharma Announces Management Additions, Promotion]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035008</link>
			<pubDate>Thu, 10 May 2012 12:58:50 GMT</pubDate>
			<author><![CDATA[Tris Pharma]]></author>
		 <description><![CDATA[MONMOUTH JUNCTION, N.J., May 10, 2012  (HSMN NewsFeed)  -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today the joining of Ms. Amanda Wohlleber as Vice President of Scale up and Technical Services effective immediately and... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Tris Pharma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Galena Biopharma Announces Expansion of Scientific Advisory Board]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035007</link>
			<pubDate>Thu, 10 May 2012 12:56:30 GMT</pubDate>
			<author><![CDATA[Galena Biopharma]]></author>
		 <description><![CDATA[LAKE OSWEGO, Ore., May 10, 2012 --(HSMN NewsFeed) -- Galena Biopharma (Nasdaq:GALE ), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced the ap... <br/><font color="red">Biopharmaceuticals, Oncology, Personnel</font><br/><font color="blue">Galena Biopharma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biosense Webster Announces Launch of the THERMOCOOL(R) SF NAV Catheter With Curve Visualization]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035006</link>
			<pubDate>Thu, 10 May 2012 12:50:50 GMT</pubDate>
			<author><![CDATA[Biosense Webster]]></author>
		 <description><![CDATA[DIAMOND BAR, Calif.--(Healthcare Sales & Marketing Network)--Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the new THERMOCOOL&reg; SF NAV irrigated ablation catheter with Curve Vis... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">Biosense Webster, THERMOCOOL SF NAV, THERMOCOOL, ablation catheter</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035005</link>
			<pubDate>Thu, 10 May 2012 12:46:10 GMT</pubDate>
			<author><![CDATA[RXi Pharmaceuticals]]></author>
		 <description><![CDATA[WORCESTER, Mass.--(Healthcare Sales & Marketing Network)--RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Geert Cauwenbergh, Dr. Med. Sc. has been appointed as the Company’s President and Chief Executive Officer. Dr. Cauwenbergh bring... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">RXi Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[LaserGen names Dr. Mimi Healy as CEO]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2035004</link>
			<pubDate>Thu, 10 May 2012 12:40:20 GMT</pubDate>
			<author><![CDATA[LaserGen]]></author>
		 <description><![CDATA[HOUSTON, May 10, 2012  (HSMN NewsFeed)  -- Emerging biotechnology company LaserGen, Inc., focused on commercializing novel technologies for next-generation sequencing (NGS), announced the appointment of Mimi Healy, Ph.D. as Chief Executive Officer (CEO) an... <br/><font color="red">Diagnostics, Personnel</font><br/><font color="blue">LaserGen</font>]]>
			</description>
	</item>
	</channel>
</rss>
